Literature DB >> 3498771

Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.

M J Campbell1, W Carroll, S Kon, K Thielemans, J B Rothbard, S Levy, R Levy.   

Abstract

C3H/HeN mice were immunized with idiotypic immunoglobulin M (IgM) and its molecular subunits from the syngeneic 38C13 lymphoma. Immunization with idiotypic IgM (38C-Id) resulted in idiotype-specific humoral and cellular immunity and protection against a lethal tumor cell challenge. Heavy (H38C) and light (L38C) chains were isolated by electroelution from preparative polyacrylamide gels. Both of these immunogens induced significant resistance to a subsequent tumor challenge. Variable region immunogens, in the form of trpE-fusion proteins, were obtained by cloning heavy and light chain variable region genes into the expression plasmid pATH-11. Of these, only the trpE-VH38C immunogen yielded immune resistance to tumor challenge. Finally, the nucleic acid sequence of 38C-Id light chain was determined and, based on the corresponding amino acid sequence and an analysis of predicted secondary structure, a region of potential antigenicity in complementarity-determining region 3 was chosen for the production of a synthetic peptide. Vaccination with this synthetic peptide resulted in significant suppression of tumor growth. Analysis of the humoral and cellular immunity generated by these vaccines revealed the presence of antibodies reactive with native idiotypic IgM only in 38C-Id, H38C, and trpE-VH38C immune sera, although the latter two were not idiotype-specific. Idiotype-specific lymphocytes, which proliferated in response to native 38C-Id, were observed in all immune animals. With the exception of the fusion protein immunogens, conjugation to an immunogenic carrier protein (keyhole limpet hemocyanin or thyroglobulin) was required for optimal humoral and cellular responses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498771

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.

Authors:  Kamran Kafi; David J Betting; Reiko E Yamada; Michael Bacica; Kristopher K Steward; John M Timmerman
Journal:  Mol Immunol       Date:  2008-11-28       Impact factor: 4.407

2.  Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry.

Authors:  Kedar G Patel; James R Swartz
Journal:  Bioconjug Chem       Date:  2011-02-28       Impact factor: 4.774

3.  Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.

Authors:  Katja Mauerer Zirlik; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

4.  The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.

Authors:  Fiona A Harding; Marcia M Stickler; Jennifer Razo; Robert B DuBridge
Journal:  MAbs       Date:  2010-05-01       Impact factor: 5.857

5.  Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.

Authors:  Suzanne N Franki; Kristopher K Steward; David J Betting; Kamran Kafi; Reiko E Yamada; John M Timmerman
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

6.  Development of orally active inhibitors of protein and cellular fucosylation.

Authors:  Nicole M Okeley; Stephen C Alley; Martha E Anderson; Tamar E Boursalian; Patrick J Burke; Kim M Emmerton; Scott C Jeffrey; Kerry Klussman; Che-Leung Law; Django Sussman; Brian E Toki; Lori Westendorf; Weiping Zeng; Xinqun Zhang; Dennis R Benjamin; Peter D Senter
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

Review 7.  Immunotherapy for lymphomas.

Authors:  John M Timmerman
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

8.  Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma.

Authors:  Sandra Iurescia; Daniela Fioretti; Pasquale Pierimarchi; Emanuela Signori; Manuela Zonfrillo; Giancarlo Tonon; Vito M Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-04-27

9.  Three new immunoglobulin kappa variable (Igk-V) gene segments in the mouse.

Authors:  D A Ramsden; G E Wu
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

10.  Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.

Authors:  John M Timmerman; Julie M Vose; Debra K Czerwinski; Wen-Kai Weng; Diane Ingolia; Martha Mayo; Dan W Denney; Ronald Levy
Journal:  Leuk Lymphoma       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.